Evidence map›Paper›PMID 34293476›Full record

ArticleGenomics2021

CoVrimer: A tool for aligning SARS-CoV-2 primer sequences and selection of conserved/degenerate primers.

Merve Vural-Ozdeniz, Aslinur Akturk, Mert Demirdizen, Ronaldo Leka, Rana Acar, Ozlen Konu

Abstract read
In one paragraph

Article in Genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Applying the digital data and the bioinformatics tools in SARS-CoV-2 research.Computational and structural biotechnology journal · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Merve Vural-OzdenizInterdisciplinary Neuroscience Program, Bilkent University, Ankara, Turkey.
Aslinur AkturkDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
Mert DemirdizenDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
Ronaldo LekaDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
Rana AcarDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
Ozlen KonuInterdisciplinary Neuroscience Program, Bilkent University, Ankara, Turkey; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. Electronic address: konu@fen.bilkent.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As mutations in SARS-CoV-2 virus accumulate rapidly, novel primers that amplify this virus sensitively and specifically are in demand. We have developed a webserver named CoVrimer by which users can search for and align existing or newly designed conserved/degenerate primer pair sequences against the viral genome and assess the mutation load of both primers and amplicons. CoVrimer uses mutation data obtained from an online platform established by NGDC-CNCB (12 May 2021) to identify genomic regions, either conserved or with low levels of mutations, from which potential primer pairs are designed and provided to the user for filtering based on generalized and SARS-CoV-2 specific parameters. Alignments of primers and probes can be visualized with respect to the reference genome, indicating variant details and the level of conservation. Consequently, CoVrimer is likely to help researchers with the challenges posed by viral evolution and is freely available at http://konulabapps.bilkent.edu.tr:3838/CoVrimer/.

Indexed as

SoftwareConserved SequenceDNA PrimersGenome, ViralMutationSARS-CoV-2Sequence Analysis, DNADNA PrimersConserved primersCOVID-19Genome alignmentMutationPrimer designSARS-CoV-2

Identifiers

PMID34293476
PMCPMC8289724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.